A meta-analysis based on individual patient-level data of the Barostim HOPE4HF and BeAT-HF trials showed that benefit of BAT in patients with HFrEF is more pronounced among patients without cardiac resynchronization therapy and serum NT-proBNP < 1600 pg/mL.26 The gene discussed is NPPB; the disease is hydrops fetalis.